Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : wla(warner lambert) -- Ignore unavailable to you. Want to Upgrade?

To: twt who wrote (420)	1/19/1999 8:20:00 AM
From: Anthony Wong	Respond to of 942

twt, currently Rezulin has a market share of 9% while Lipitor's market share is 42.5%. Lipitor is the biggest moneymaker for WLA, while Rezulin is a close second. When the company released its last earnings report (in October), it stated that it is comfortable with analyst estimates of $1.48 for 1998 and 30% earnings growth in 1999. Some analysts estimated 35-40% growth. Anyway, that is a higher growth rate than most big pharmas'. There's a Bloomberg article at Post #407 that provided more info about the Rezulin issue. You may also wish to do some research on the company's pipeline etc. and WLA's website is a good place to start: warner-lambert.com I beleive that many big pharmas are still good long term core holdings. Why not do some dd on a few better big pharmas and then make use of individual stock's price weakness to do some dollar-cost averaging buying. P.S. I'm not a medical professional. I'm just a regular investor of pharma stocks. My first investment in big pharmas was some 10 years ago (in GLX and MRK). BigK has even more experience in big phrarma investing (over 30 years, I believe). Best regards. Anthony

To: twt who wrote (420)	1/19/1999 8:52:00 AM
From: Anthony Wong	Read Replies (1) \| Respond to of 942

Warner-Lambert Reiterated 'Buy' at PaineWebber, target $93 Bloomberg News January 19, 1999, 8:15 a.m. ET Princeton, New Jersey, Jan. 19 (Bloomberg Data) -- Warner-Lambert Co. (WLA US) was reiterated ''buy'' by analyst Jeffrey Chaffkin at PaineWebber Inc. The 12-month target price is $93.00 per share. -- Andrew Bekoff in Princeton, New Jersey, (609)279-3652